Takako Okumura

This inventor holds 13 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 8 EPO patents. Top assignees: Askat Inc., Raqualia Pharma Inc., Arrys Therapeutics, Inc.. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takako Okumura. Retrieved from https://idiyas.com/inventor/takako-okumura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 5)

% Patents Active = 92.3

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 35(Granted Patents)

Location History:

Nagoya, JP (2021)
Aichi, JP (2014 - 2023)

Company Filing History:

Arrys Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11840530 - Selective EP4 receptor antagonistic substance for treatment of cancer (2023-12-12),

2. 10973834 - EP4 inhibitors and use thereof (2021-04-13),

3. 10947235 - Selective EP4 receptor antagonistic substance for treatment of cancer (2021-03-16),

4. 10786490 - Use of EP4 receptor antagonists in the treatment of cartilage disease (2020-09-29),

5. 10611761 - Selective EP4 receptor antagonistic substance for treatment of cancer (2020-04-07),

6. 10583129 - Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (2020-03-10),

7. 10391086 - Use of EP4 receptor antagonists in the treatment of cartilage disease (2019-08-27),

8. 10342785 - Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (2019-07-09),

9. 9688674 - Selective EP4 receptor antagonistic substance for treatment of cancer (2017-06-27),

10. 9561210 - Therapeutic agent for ocular disease (2017-02-07),

11. 9457084 - Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases (2016-10-04),

12. 9447066 - Salts and crystal forms (2016-09-20),

13. 8921391 - Selective EP4 receptor antagonistic substance for treatment of cancer (2014-12-30),

Title: Takako Okumura: Pioneering Cancer Innovations from Aichi, Japan

Introduction

Takako Okumura, an accomplished inventor based in Aichi, Japan, has made significant strides in the field of medicinal chemistry. With a total of 13 patents to her name, she has dedicated her expertise towards developing innovative treatments for cancer. Her work merges scientific knowledge with practical applications, showcasing her commitment to improving patient outcomes.

Latest Patents

Among her most recent creations is a selective EP4 receptor antagonistic substance aimed at treating cancer. This groundbreaking invention introduces a medicament that reduces cancer growth through the inhibition of the prostaglandin E2 receptor (EP4). It encompasses compounds represented by several specific formulas, alongside pharmaceutically acceptable salts or compositions intended for the manufacture of cancer treatments. Furthermore, the method outlined includes administering these compounds to humans or animals, potentially in conjunction with additional active agents.

Another significant patent involves the use of agents that inhibit EP4 activity combined with immuno-oncology agents for cancer treatment. This patent emphasizes the innovative aspect of combining different therapeutic strategies to enhance the efficacy of cancer therapies.

Career Highlights

Takako has had a notable career, having worked with respected organizations such as Askat Inc. and Raqualia Pharma Inc. Throughout her career, she has focused on creating pharmaceutical solutions that tackle complex health challenges, particularly in oncology.

Collaborations

Collaboration is vital in scientific research, and Takako has worked alongside talented professionals such as Shinichi Koizumi and Yukinori Take. Their joint efforts aim to drive forward-thinking solutions and establish new frontiers in cancer treatment.

Conclusion

Takako Okumura exemplifies the essence of innovation in the realm of medicine. Her dedication to advancing cancer therapy through her patented inventions not only demonstrates her intellect but also her commitment to enhancing the quality of life for patients battling cancer. As research and development continue to evolve, contributions from inventors like Takako are vital in shaping the future of healthcare.

Profile summary based on public USPTO records.